Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
OHSU Knight Cancer Institute
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00335478CT.gov Daptomycin in Treating Neutropenia and Fever in Patients With Cancer | — | Completed | — | — | — |
NCT00296049CT.gov Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Daptomycin (this asset) | OHSU Knight Cancer Institute | P2 | CCC · 52 |
| Sulfamethoxazole | Radboud University Medical Center | P4 | A |
| Trimethoprim | Radboud University Medical Center | P4 | A |
| Ciprofloxacin | Radboud University Medical Center | P4 | BBB |
| Amdinocillin | Radboud University Medical Center | P4 | BB |
| Aztreonam | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BB |
| Nivestim | Cellerant Therapeutics | P3 | BB |
| Fosfomycin | Radboud University Medical Center | P4 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
+40 more in the Infectious Disease cohort
Other indications for Daptomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hematopoietic And Lymphoid Cell Neoplasm | — | P2 | CCC · 52 |
| Cancer | — | P2 | CCC · 52 |
| Sweat Gland Disorder | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Daptomycin in Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/daptomycin-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →